HomeAI · summaries
Storia in 3 fonti
AI titans push Congress for DNA safeguards
Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Legend Biotech emerged as a rare market winner
New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout
- ·
Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
Alnylam announced a three-year deal with Inceptive Nucleics, worth up to $2 billion, with $30 million upfront in cash and equity in the startup.
- ·
endpoints.news
Alnylam signs its first AI discovery deal with RNA specialist Inceptive
Alnylam will pay $30 million upfront for its first discovery-focused AI deal, tapping a Silicon Valley biotech startup to see if AI can boost its R&D efforts.
- ·
biopharmadive.com
Alnylam, Inceptive ink AI deal potentially worth $2B
The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.
- ·
AI titans push Congress for DNA safeguards
Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout